1. Activation of Tyrosine Phosphorylation Signaling in Erythrocytes of Patients with Alzheimer’s Disease
- Author
-
Nicola Vanacore, Federica Perrone, Carmen D'Amore, Annamaria Confaloni, Giuseppe Bruno, Alessio Crestini, Marisa Cappella, Paola Piscopo, Giuseppina Talarico, and Cinzia Mallozzi
- Subjects
0301 basic medicine ,Erythrocytes ,Peptide ,Protein tyrosine phosphatase ,environment and public health ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Alzheimer Disease ,LYN ,medicine ,Humans ,Dementia ,Phosphorylation ,Aged ,Aged, 80 and over ,chemistry.chemical_classification ,business.industry ,General Neuroscience ,Tyrosine phosphorylation ,Transporter ,medicine.disease ,In vitro ,enzymes and coenzymes (carbohydrates) ,030104 developmental biology ,chemistry ,Cancer research ,Tyrosine ,business ,030217 neurology & neurosurgery ,Signal Transduction - Abstract
Alzheimer's disease (AD) is the most prevalent type of dementia affecting older people. The identification of biomarkers is increasingly important and would be crucial for future therapy. Here, we demonstrated that in AD erythrocytes: (i) the anion transporter band3 is highly phosphorylated; (ii) the lyn kinase is phosphorylated and activated; (iii) the tyrosine phosphatase activity is downregulated, with a significant inverse correlation between band3 phosphorylation and disease progression, as revealed by Mini Mental State Examination score. Finally, we showed that in normal erythrocytes, treated in vitro with Aβ1-42 peptide, both band3 phosphorylation and lyn activation occurs. These results suggest that modulation of tyrosine phosphorylation signaling may be evaluated as a potential peripheral marker in AD.
- Published
- 2020
- Full Text
- View/download PDF